Elimination of hepatitis C virus in a prison: An 18-year experience

World Health Organization. Hepatitis C [Internet]. 2019 [accessed 9 Jan 2022]. Available from: https://www.who.int/es/news-room/fact-sheets/detail/hepatitis-c. Grupo de trabajo del estudio de prevalencia de la infección por hepatitis C en población general en España; 2017-2018. Resultados del 2.º estudio de seroprevalencia en España (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019. Larney, 2013, Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis, Hepatology., 58, 1215, 10.1002/hep.26387 Zampino, 2015, Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment, World J Hepatol., 7, 2323, 10.4254/wjh.v7.i21.2323 Secretaría General de Instituciones Penitenciarias. Subdirección General de Coordinación de Sanidad Penitenciaria. Prevalencia de las infecciones VIH y VHC en Instituciones Penitenciarias. Año 2018. [Internet]. 2018 [accessed 9 Jan 2022]. Available from: http://www.institucionpenitenciaria.es/web/export/sites/default/datos/descargables/saludpublica/Prevalencia_VIH_y_VHC_en_IIPP_2018.pdf. Nogales Garcia, 2017, III Congreso Nacional del Grupo de Estudio de las Hepatitis Víricas (GEHEP) de la SEIMC. P-079. Evolución del virus de la hepatitis C en pacientes institucionalizados en un centro penitenciario, Enferm Infecc Microbiol Clin., 35, 36 Feld, 2015, Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection, N Engl J Med., 373, 2599, 10.1056/NEJMoa1512610 Marco, 2014, Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period, PLoS ONE., 9, 10.1371/journal.pone.0090560 Stöver, 2019, Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and Practice Assessment in Europe, BMC Public Health., 19, 30, 10.1186/s12889-018-6357-x European Centre for Disease Prevention and Control. Public health guidance on prevention and control of blood-borne viruses in prison settings: prevention and control of communicable diseases in prison settings. [Internet]. 2018 [accessed 27 Nov 2022]. Available from: https://data.europa.eu/doi/10.2900/042079. World Health Organization. Access to hepatitis C testing and treatment for people who inject drugs and people in prisons: A global perspective: Policy brief, April 2019 [Internet]. World Health Organization; 2019 [accessed 27 Nov 2022]. Available from: https://apps.who.int/iris/handle/10665/312116. World Health Organization. Estrategia Mundial del sector de la salud contra las hepatitis vÍricas 2016-2021: Hacia el fin de las hepatitis víricas [Internet]. World Health Organization; 2016 [accessed 9 Jan 2022]. Available from: https://apps.who.int/iris/handle/10665/250578. Lazarus, 2017, Micro-elimination – a path to global elimination of hepatitis C, J Hepatol., 67, 665, 10.1016/j.jhep.2017.06.033 Secretaría General de Sanidad y Consumo. Ministerio de Sanidad, Consumo y Bienestar Social. Plan Estratégico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud (PEAHC) [Internet]. Ministerio de Sanidad, Consumo y Bienestar Social. 2018 [accessed 9 Jan 2022]. Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/Plan_Estrategico_Abordaje_Hepatitis_C_(PEAHC).pdf. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults [Internet]. Centers for Disease Control and Prevention. 1992 [accessed 27 Nov 2022]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet., 358, 958, 10.1016/S0140-6736(01)06102-5 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med., 347, 975, 10.1056/NEJMoa020047 Wright, 2002, Treatment of patients with hepatitis C and cirrhosis, Hepatology., 36, S185 Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med., 364, 1195, 10.1056/NEJMoa1010494 Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med., 364, 2405, 10.1056/NEJMoa1012912 Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med., 364, 1207, 10.1056/NEJMoa1009482 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med., 364, 2417, 10.1056/NEJMoa1013086 Departamento de Medicamentos de Uso Humano. Agencia Española del Medicamento y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de posicionamiento terapéutico de glecaprevir/pibrentasvir. IPT, 8/2018. V1. [Internet]. [accessed 9 Jan 2022]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-glecaprevir-pibrentasvir-Maviret-hepatitisC.pdf. Departamento de Medicamentos de Uso Humano. Agencia Española del Medicamento y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terapéutico de sofosbuvir/velpatasvir en hepatitis C. IPT, 19/2017. V1. [Internet] [accessed 9 Jan 2022]. Available from: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-sofosbuvir-velpatasvir-Epclusa-hepatitisC.pdf. Marco, 2019, Is it possible to eliminate hepatitis C from the prisons of Catalonia, Spain, in 2021?, Rev Esp Sanid Penit., 21, 38, 10.4321/S1575-06202019000100006 Marco Mourino, 2016, Interrupción del tratamiento de la hepatitis C crónica con antivirales de acción directa por causas de origen penitenciario en las prisiones de Cataluña, Rev Esp Sanid Penit., S18, 88 Touzón-López, 2016, Eficacia, seguridad y discontinuación del tratamiento de la Hepatitis C Crónica con antivirales de acción directa en las prisiones de Cataluña, Rev Esp Sanid Penit., S18, 87 De Juan, 2014, Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study), Eur J Gastroenterol Hepatol., 26, 1083, 10.1097/MEG.0000000000000163 Vroling, 2018, A systematic review on models of care effectiveness and barriers to hepatitis C treatment in prison settings in the EU/EEA, J Viral Hepat., 25, 1406, 10.1111/jvh.12998 Marco, 2018, Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates, J Viral Hepat., 25, 1280, 10.1111/jvh.12940